Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$19.72
+1.9%
$18.11
$16.10
$42.47
$2.48B0.672.36 million shs230,990 shs
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$21.21
+0.9%
$19.18
$14.06
$27.29
$2.38B-0.03737,419 shs79,479 shs
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$9.16
-0.2%
$7.78
$4.62
$13.47
$573.30M0.291.33 million shs556,265 shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$36.34
-0.1%
$33.47
$27.12
$60.90
$2.18B2.411.09 million shs222,379 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-2.81%+8.16%+2.76%+6.55%-51.63%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-5.19%+5.00%+4.01%+31.13%+7.30%
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
+0.22%+0.11%+36.87%+24.42%-22.29%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-3.78%-1.65%+8.50%-5.41%-35.23%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
4.2319 of 5 stars
4.30.00.04.42.12.50.6
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
2.7421 of 5 stars
3.52.00.00.01.65.00.0
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
3.4162 of 5 stars
2.04.00.04.11.81.70.6
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.1837 of 5 stars
3.45.00.04.41.40.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.62
Moderate Buy$39.84102.05% Upside
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
3.00
Buy$42.89102.26% Upside
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
1.94
Reduce$8.75-4.46% Downside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4038.69% Upside

Current Analyst Ratings Breakdown

Latest SAGE, APLS, NAMS, and TWST Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$23.00 ➝ $24.00
7/8/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$12.00 ➝ $9.20
7/2/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $26.00
6/20/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$7.00 ➝ $9.00
6/17/2025
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$42.00
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$9.00 ➝ $8.50
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetHold ➝ Hold$8.00 ➝ $9.00
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$12.00
6/17/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$8.00 ➝ $8.50
6/16/2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
6/12/2025
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$40.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$775.84M3.19N/AN/A$1.84 per share10.72
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
$45.56M52.25N/AN/A$8.20 per share2.59
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
$47.40M12.09N/AN/A$7.60 per share1.20
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$347.68M6.26N/AN/A$8.07 per share4.50
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$197.88M-$1.79N/AN/AN/A-28.83%-99.19%-25.35%7/30/2025 (Estimated)
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$241.60M-$1.88N/AN/AN/A-397.45%-37.34%-33.45%8/6/2025 (Estimated)
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$400.67M-$5.80N/AN/AN/A-747.63%-68.99%-60.67%7/30/2025 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/4/2025 (Confirmed)

Latest SAGE, APLS, NAMS, and TWST Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$0.44N/AN/AN/AN/AN/A
8/6/2025Q2 2025
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.52N/AN/AN/A$1.44 millionN/A
8/1/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54N/AN/AN/A$95.52 millionN/A
7/30/2025Q2 2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$0.96N/AN/AN/A$16.69 millionN/A
5/8/2025Q1 2025
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
-$0.45-$0.49-$0.04-$0.34$1.46 million$2.98 million
5/7/2025Q1 2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$0.36-$0.74-$0.38-$0.74$197.61 million$149.90 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
4/29/2025Q1 2025
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
-$0.99-$1.01-$0.02-$1.01$14.12 million$14.06 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.76
4.08
3.62
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
N/A
19.98
19.98
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
N/A
9.13
9.13
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24

Institutional Ownership

CompanyInstitutional Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
89.89%
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
99.22%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
6.80%
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
20.84%
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
5.50%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770125.68 million117.14 millionOptionable
NewAmsterdam Pharma Company N.V. stock logo
NAMS
NewAmsterdam Pharma
4112.27 million88.87 millionOptionable
Sage Therapeutics, Inc. stock logo
SAGE
Sage Therapeutics
69062.62 million59.18 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable

Recent News About These Companies

Twist Bioscience: Still Not There Yet

New MarketBeat Followers Over Time

Media Sentiment Over Time

Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

$19.72 +0.37 (+1.91%)
As of 12:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$21.20 +0.19 (+0.88%)
As of 12:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Sage Therapeutics stock logo

Sage Therapeutics NASDAQ:SAGE

$9.15 -0.02 (-0.16%)
As of 12:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$36.34 -0.03 (-0.09%)
As of 12:06 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.